Harsaul Foundation

Harsaul Foundation discloses dealings in RVL Pharmaceuticals plc to SEC (Form 4). We count 4 filings; the first trade dates from 13 January 2020 and the latest from 20 October 2023.

On the open market, the record shows 1 purchase worth €5.6M and 3 sales worth €758k. Taken together, the purchases exceed the sales by €4.9M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2023: no purchases and 3 sales on the market.

On 23 October 2023 came the latest disclosure, an open-market sale for €140k in RVL Pharmaceuticals plc. The latest purchase dates back some time: it was published 2,489 days ago, on 15 January 2020. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.